Nervgen Pharma Corp (NGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2005 | 12-2004 | 12-2003 | 12-2002 | 12-2001 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -96,490 | -38,900 | -30,590 | -22,240 | -32,500 |
| Depreciation Amortization | 4,870 | 4,370 | 4,660 | 4,180 | 3,470 |
| Other Working Capital | -2,320 | -2,280 | -1,180 | 2,340 | -5,770 |
| Other Operating Activity | 59,330 | 7,320 | 1,640 | -12,730 | 1,820 |
| Operating Cash Flow | $-34,610 | $-29,490 | $-25,470 | $-28,450 | $-32,980 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -1,320 | -800 | -1,170 | -130 | -650 |
| Net Acquisitions | 0 | 3,500 | 0 | 0 | 0 |
| Other Investing Activity | 6,720 | -16,490 | 16,610 | 26,650 | -16,400 |
| Investing Cash Flow | $5,400 | $-13,790 | $15,440 | $26,520 | $-17,050 |
| Cash Flows From Financing Activities | |||||
| Other Financing Activity | 20,080 | 49,970 | 8,930 | 350 | 5,150 |
| Financing Cash Flow | $20,080 | $49,970 | $8,930 | $350 | $5,150 |
| Exchange Rate Effect | -50 | 130 | 290 | 470 | 5 |
| Beginning Cash Position | 15,370 | 8,550 | 9,350 | 10,450 | 55,330 |
| End Cash Position | 6,190 | 15,370 | 8,550 | 9,350 | 10,450 |
| Net Cash Flow | $-9,170 | $6,820 | $-800 | $-1,100 | $-44,870 |
| Free Cash Flow | |||||
| Operating Cash Flow | -34,610 | -29,490 | -25,470 | -28,450 | -32,980 |
| Free Cash Flow | -34,610 | -29,490 | -25,470 | -28,450 | -32,980 |